China Resources Pharmaceutical Group Limited

HKSE 3320.HK

China Resources Pharmaceutical Group Limited Debt to Equity Ratio for the year ending December 31, 2023: 1.23

China Resources Pharmaceutical Group Limited Debt to Equity Ratio is 1.23 for the year ending December 31, 2023, a -9.13% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • China Resources Pharmaceutical Group Limited Debt to Equity Ratio for the year ending December 31, 2022 was 1.35, a -16.55% change year over year.
  • China Resources Pharmaceutical Group Limited Debt to Equity Ratio for the year ending December 31, 2021 was 1.62, a 28.39% change year over year.
  • China Resources Pharmaceutical Group Limited Debt to Equity Ratio for the year ending December 31, 2020 was 1.26, a -5.79% change year over year.
  • China Resources Pharmaceutical Group Limited Debt to Equity Ratio for the year ending December 31, 2019 was 1.34, a -16.71% change year over year.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
SV Wall Street
HKSE: 3320.HK

China Resources Pharmaceutical Group Limited

CEO Mr. Ran Tao
IPO Date Oct. 28, 2016
Location Hong Kong
Headquarters China Resources Building
Employees 72,764
Sector Health Care
Industries
Description

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.

Similar companies

2607.HK

Shanghai Pharmaceuticals Holding Co., Ltd

USD 1.60

0.80%

1530.HK

3SBio Inc.

USD 0.80

1.12%

0867.HK

China Medical System Holdings Limited

USD 0.93

2.39%

0570.HK

China Traditional Chinese Medicine Holdings Co. Limited

USD 0.25

2.62%

StockViz Staff

January 31, 2025

Any question? Send us an email